Baird Reiterates an 'Outperform' on Alexion Pharmaceuticals (ALXN); Raising N-T Estimates Ahead of Qtr

Baird reiterates an 'Outperform' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $110.00 (from $100.00).

Analyst, Christopher Raymond, said, "While management provided detailed color around Q212 last quarter, we think the operational flexibility of this business model, coupled with real revenue upside potential from the ongoing Soliris aHUS launch can make for yet another quarterly beat. As such, we are raising our Q212 EPS estimate to $0.38 from $0.35...Despite a higher-than-average valuation, we think this name can continue to work higher."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $97.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings